The FOXO4-DRI Cycle Question
The animal work ran for five days. Cycling vocabulary assumes something this compound does not do.
A FOXO4-DRI peptide cycle imports vocabulary from performance pharmacology onto a compound that does not work that way. The published animal dosing was three administrations across five days, and there is no human schedule of any length because no human has received it in a registered trial.
Where the order actually gets placed
Ascension Peptides, FOXO4-DRI
US-based and third-party tested. Enter the code on the payment step and the vial halves before you confirm.
The two published certificates cover different batches and disagree on net content: Kovera Labs assayed batch 55-05260628 at 11.41 mg, MZ Biolabs assayed lot 55-01260229 at 8.30 mg, both against a 10 mg label. Endotoxin and sterility screens appear on the Kovera batch only. The vendor spells the product FOX04 with a zero, including in the link. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- Two batch certificates per lot
- Shipping free over $250
- Out the door same day if you order before 2pm CST
Everything here is research material for laboratory use, not for human consumption. FOXO4-DRI is not an approved medicine in any market and has never been tested in a human trial. Affiliate links, so we may earn a commission at no cost to you. Prices last checked September 2, 2026.
Why the frame does not fit
Cycling assumes a compound that must be present to have an effect: hold a receptor occupied, sustain a signal, accumulate an adaptation, then withdraw and recover. Duration is the variable because exposure is the mechanism.
A senolytic inverts that. It eliminates a cell population, and once those cells are gone there is nothing left to act on until they re-accumulate, which takes months and years rather than hours. Exposure beyond the point of clearance adds risk without adding benefit.
| | A cycle, as usually meant | The published senolytic dosing | | --- | --- | --- | | Purpose | Sustain a signal to drive adaptation | Clear a population, then stop | | Duration | Weeks, planned in advance | Three doses across five days | | After stopping | Effect fades as levels fall | Persists until cells re-accumulate | | Reason to stop | Suppression, tolerance, risk accrual | Nothing left to act on | | Recovery needed | Often | Nothing to recover from |
What the animal dosing actually was
In the 2017 study, mice received FOXO4-DRI at 5 mg/kg on days 1, 3 and 5. Route was intravenous in the chemotoxicity experiments and intraperitoneal in the ageing cohorts. Doxorubicin, used to drive cells into senescence in that model, was given separately at 10 mg/kg in mice.
Three administrations, alternating days, then nothing. That is the entire published schedule, and it is an experimental design in mice rather than a template for a person.
Scaling it by body weight is a calculation you can perform and not a dose you can rely on. Allometric scaling estimates a starting point for formal study and requires pharmacokinetic inputs that do not exist for this peptide in humans: no measured half-life, no bioavailability, no clearance route.
It is not an anabolic compound
Worth stating directly, because the cycle framing usually arrives from that world.
FOXO4-DRI does not bind an androgen receptor, does not stimulate growth hormone release, does not influence protein synthesis, and has never been measured against a muscle, strength or performance endpoint in any species. There is not even a null result to report, because the experiment has not been run.
The legitimate reason to follow senolytics is that senescent cells accumulate in ageing tissue and their inflammatory secretions are implicated in declining repair capacity. That is a maintenance hypothesis rather than a growth claim, and it has not been tested in humans with this compound.
What this page does not contain
No cycle length, no stacking suggestions, no schedule for a person. Not because it is being withheld but because it does not exist.
FOXO4-DRI holds no approval from the FDA, the EMA or the MHRA, and ClinicalTrials.gov lists no registered interventional study of it in humans. There is no established dose, no measured half-life in people, no tolerability data and no adverse-event record.
There is also a reason for caution beyond the absence of data. A 2023 study found that eliminating senescent cells could promote the development and progression of pulmonary hypertension, so the effects are not uniformly in the direction the enthusiasm assumes.